Romosozumab-Aqqg
Last Updated: 02/24/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Comparison table: Some drugs for postmenopausal osteoporosis.
Journal: The Medical letter on drugs and therapeutics
Published: July 09, 2024
Drugs for postmenopausal osteoporosis.
Journal: The Medical letter on drugs and therapeutics
Published: July 09, 2024
Bone union-promoting effect of romosozumab in an ovariectomized rat posterolateral lumbar fusion model.
Journal: Journal of orthopaedic research : official publication of the Orthopaedic Research Society
Published: August 03, 2023
Loss of Nmp4 enhances bone gain from sclerostin antibody administration.
Journal: Bone
Published: July 05, 2023
A breakthrough in the management of postmenopausal osteoporosis with very high fracture risk : romosozumab (Evenity®), a humanized monoclonal anti-sclerostin antibody
Journal: Revue medicale de Liege
Published: April 17, 2023
Evaluation of the efficacy and safety of romosozumab (evenity) for the treatment of osteoporotic vertebral compression fracture in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials (CDM-J).
Journal: Pharmacoepidemiology and drug safety
Published: December 08, 2022
Romosozumab-aqqg in the Treatment of Osteoporosis in a Patient With Hypophosphatasia.
Journal: Journal of the Endocrine Society
Published: July 08, 2022
Romosozumab: A Novel Agent in the Treatment for Postmenopausal Osteoporosis.
Journal: The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians
Published: November 09, 2021
Bone union-promoting effect of romosozumab in a rat posterolateral lumbar fusion model.
Journal: Journal of orthopaedic research : official publication of the Orthopaedic Research Society
Published: August 11, 2021
Last Updated: 02/24/2026